Jamie Wilder
Family · Barbourville, KYNPI 1134679806
Payments from drug & device makers
Across 560 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Lilly USA, LLC$660
- Bayer$583
- AstraZeneca$422
- Novo Nordisk$412
- plus $4K from 25 others
What the payments were for
- Food & beverage$8,476100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 105 | $1,435 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 73 | $1,064 |
| Lilly USA, LLC | 52 | $660 |
| Bayer | 27 | $583 |
| AstraZeneca | 16 | $422 |
| Novo Nordisk | 36 | $412 |
| Sanofi | 18 | $355 |
| Biohaven Pharmaceuticals, Inc. | 22 | $354 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $328 |
| Johnson & Johnson | 16 | $281 |
| Amgen | 18 | $271 |
| Pfizer | 16 | $223 |
| Phathom Pharmaceuticals, Inc. | 20 | $219 |
| Sanofi-aventis U.S. LLC | 14 | $211 |
| Biohaven Pharmaceutical Holding Company Ltd. | 17 | $211 |
| Gilead | 10 | $204 |
| Astellas Pharma US Inc | 10 | $163 |
| Amarin Pharma, Inc. | 11 | $158 |
| Daiichi Sankyo Inc. | 10 | $157 |
| Regeneron Healthcare Solutions, Inc. | 8 | $149 |
| Madrigal Pharmaceuticals | 8 | $133 |
| Ardelyx, Inc. | 6 | $116 |
| Averitas Pharma Inc. | 6 | $106 |
| Novartis | 3 | $54 |
| GSK | 3 | $53 |
| Exact Sciences | 3 | $45 |
| Boehringer Ingelheim | 3 | $39 |
| QOL Medical, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,476 in reported general payments places this provider in the 95th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $60,497 |
| MounjaroTirzepatide | 42 | $52,447 |
| FarxigaDapagliflozin Propanediol | 47 | $43,992 |
| LinzessLinaclotide | 35 | $43,416 |
| JardianceEmpagliflozin | 30 | $38,777 |
| EliquisApixaban | 33 | $26,482 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $20,523 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,166 |
| EntrestoSacubitril/Valsartan | 12 | $11,395 |
| VascepaIcosapent Ethyl | 18 | $11,372 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,861 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $5,532 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 20 | $5,279 |
| Celecoxib | 50 | $4,306 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 121 | $3,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $422 | $64,51573 claims |
| Novo NordiskOzempic | $412 | $60,49752 claims |
| Lilly USA, LLCMounjaro | $660 | $52,44742 claims |
| AbbVieLinzess, Synthroid | $1,435 | $43,98046 claims |
| Boehringer IngelheimJardiance | $39 | $38,77730 claims |
| PfizerEliquis | $223 | $26,48233 claims |
| GSKTrelegy Ellipta | $53 | $13,16620 claims |
| NovartisEntresto | $54 | $11,39512 claims |
| Sanofi-aventis U.S. LLCLantus | $211 | $2,62820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,374 family providers in Kentucky.
Other family in Barbourville
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.